Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 22, 2019

SELL
$2.08 - $3.36 $3,625 - $5,856
-1,743 Closed
0 $0
Q3 2018

Nov 09, 2018

BUY
$2.6 - $3.59 $4,531 - $6,257
1,743 New
1,743 $6,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $4.5B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Proffitt & Goodson Inc Portfolio

Follow Proffitt & Goodson Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Proffitt & Goodson Inc, based on Form 13F filings with the SEC.

News

Stay updated on Proffitt & Goodson Inc with notifications on news.